232 related articles for article (PubMed ID: 31305170)
1. Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
Santambrogio E; Nicolosi M; Vassallo F; Castellino A; Novo M; Chiappella A; Vitolo U
Expert Rev Hematol; 2019 Sep; 12(9):787-796. PubMed ID: 31305170
[No Abstract] [Full Text] [Related]
2. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
Ferreri AJ; Assanelli A; Crocchiolo R; Ciceri F
Hematol Oncol; 2009 Jun; 27(2):61-70. PubMed ID: 19247977
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.
Haioun C; Besson C; Lepage E; Thieblemont C; Simon D; Rose C; Tilly H; Sonet A; Lederlin P; Attal M; Brière J; Reyes F
Ann Oncol; 2000 Jun; 11(6):685-90. PubMed ID: 10942056
[TBL] [Abstract][Full Text] [Related]
4. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
6. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).
Kawamura T; Koga S; Okamoto M; Kanno T; Iwamura H
Radiat Med; 2001; 19(3):145-9. PubMed ID: 11467381
[TBL] [Abstract][Full Text] [Related]
7. How I treat patients with aggressive lymphoma at high risk of CNS relapse.
Chin CK; Cheah CY
Blood; 2017 Aug; 130(7):867-874. PubMed ID: 28611025
[TBL] [Abstract][Full Text] [Related]
8. Prevention and management of secondary central nervous system lymphoma.
Bobillo S; Khwaja J; Ferreri AJM; Cwynarski K
Haematologica; 2023 Mar; 108(3):673-689. PubMed ID: 36384246
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.
Bromberg JE; Doorduijn JK; Illerhaus G; Jahnke K; Korfel A; Fischer L; Fritsch K; Kuittinen O; Issa S; van Montfort C; van den Bent MJ
Haematologica; 2013 May; 98(5):808-13. PubMed ID: 23144196
[TBL] [Abstract][Full Text] [Related]
10. The risk of CNS involvement in aggressive lymphomas in the rituximab era.
Benevolo G; Chiappella A; Vitolo U
Expert Rev Hematol; 2013 Dec; 6(6):643-52. PubMed ID: 24168678
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
12. Central Nervous System Involvement of Natural Killer and T Cell Neoplasms.
Aaroe AE; Nevel KS
Curr Oncol Rep; 2019 Mar; 21(5):40. PubMed ID: 30919085
[TBL] [Abstract][Full Text] [Related]
13. Secondary central nervous system lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Int J Hematol; 2006 Aug; 84(2):128-35. PubMed ID: 16926134
[TBL] [Abstract][Full Text] [Related]
14. Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
Orellana-Noia V; Abousaud A
Curr Treat Options Oncol; 2022 Oct; 23(10):1443-1456. PubMed ID: 36127571
[TBL] [Abstract][Full Text] [Related]
15. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis.
Hollender A; Kvaloy S; Lote K; Nome O; Holte H
Eur J Cancer; 2000 Sep; 36(14):1762-8. PubMed ID: 10974623
[TBL] [Abstract][Full Text] [Related]
17. Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Herrlinger U; Hebart H; Kanz L; Dichgans J; Weller M
J Neurol; 2005 Nov; 252(11):1409-10. PubMed ID: 15895304
[No Abstract] [Full Text] [Related]
18. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M; Ferreri AJ
Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
[TBL] [Abstract][Full Text] [Related]
19. CNS prophylaxis in aggressive B-cell lymphoma.
Wilson MR; Bobillo S; Cwynarski K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):138-145. PubMed ID: 36485105
[TBL] [Abstract][Full Text] [Related]
20. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
